Subependymální obrovskobuněčný astrocytom u pacientů s tuberózní sklerózou – farmakologická léčba mTOR inhibitory
| Title in English | Subependymal Giant Cell Astrocytoma Associated with Tuberous Sclerosis Complex - Pharmacological Treatment using mTOR Inhibitors |
|---|---|
| Authors | |
| Year of publication | 2014 |
| Type | Article in Periodical |
| Magazine / Source | Klinická onkologie |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.14735/amko2014401 |
| Field | Oncology and hematology |
| Keywords | subependymal giant cell astrocytoma; tuberous sclerosis complex; mTOR; everolimus |
| Description | Tuberous sclerosis complex is a neurocutaneous syndrome that results from a germline muta-tion in TSC1 or TSC2 genes. The pathogenic activation of mTORCI leads to the development of subependymal giant cell astrocytomas in patients with tuberous sclerosis complex. Blocking of the dysregulated pathway with mTOR inhibitors has the potential to reduce the volume of this low-grade brain tumor. This article reviews the current knowledge on the pharmacolo¬gical treatment of subependymal giant cell astrocytomas. A long-term follow-up and early therapeutic intervention should lead to mortality and morbidity reduction and quality of life improvement in patients with tuberous sclerosis complex associated tumors. |
| Related projects: |